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Abstract
AIM: To assesses the safety and efficacy of Aspergillus 
niger  prolyl endoprotease (AN-PEP) to mitigate the im-
munogenic effects of gluten in celiac patients.
METHODS: Patients with initial diagnosis of celiac dis-
ease as confirmed by positive serology with subtotal or 
total villous atrophy on duodenal biopsies who adhere 
to a strict gluten-free diet (GFD) resulting in normalised 
antibodies and mucosal healing classified as Marsh 0 or 
Ⅰ were included. In a randomised double-blind place-
bo-controlled pilot study, patients consumed toast (ap-
proximately 7 g/d gluten) with AN-PEP for 2 wk (safety 
phase). After a 2-wk washout period with adherence of 
the usual GFD, 14 patients were randomised to gluten 
intake with either AN-PEP or placebo for 2 wk (efficacy 
phase). Measurements at baseline included complaints, 
quality-of-life, serum antibodies, immunophenotyping 
of T-cells and duodenal mucosa immunohistology. Fur-
thermore, serum and quality of life questionnaires were 
collected during and after the safety, washout and effi-
cacy phase. Duodenal biopsies were collected after the 
safety phase and after the efficacy phase. A change in 
histological evaluation according to the modified Marsh 
classification was the primary endpoint.
RESULTS: In total, 16 adults were enrolled in the 
study. No serious adverse events occurred during the 
trial and no patients withdrew during the trial. The 
mean score for the gastrointestinal subcategory of 
the celiac disease quality (CDQ) was relatively high 
throughout the study, indicating that AN-PEP was well 
tolerated. In the efficacy phase, the CDQ scores of 
patients consuming gluten with placebo or gluten with 
AN-PEP did not significantly deteriorate and moreover 
no differences between the groups were observed. 
During the efficacy phase, neither the placebo nor the 
AN-PEP group developed significant antibody titers. 
The IgA-EM concentrations remained negative in both 
groups. Two patients were excluded from entering the 
efficacy phase as their mucosa showed an increase of 
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two Marsh steps after the safety phase, yet with unde-
tectable serum antibodies, while 14 patients were con-
sidered histologically stable on gluten with AN-PEP. Also 
after the efficacy phase, no significant deterioration 
was observed regarding immunohistological and flow 
cytometric evaluation in the group consuming placebo 
compared to the group receiving AN-PEP. Furthermore, 
IgA-tTG deposit staining increased after 2 wk of gluten 
compared to baseline in four out of seven patients on 
placebo. In the seven patients receiving AN-PEP, one 
patient showed increased and one showed decreased 
IgA-tTG deposits. 
CONCLUSION: AN-PEP appears to be well tolerated. 
However, the primary endpoint was not met due to lack 
of clinical deterioration upon placebo, impeding an ef-
fect of AN-PEP. 
© 2013 Baishideng. All rights reserved.
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INTRODUCTION
Celiac disease (CD) is a major health care issue affect-
ing people of  all ages, with a worldwide prevalence of  
approximately 1%[1]. This immune-mediated small intes-
tinal enteropathy is triggered by gluten proteins derived 
from wheat, barley and rye. Celiac disease is character-
ised by an inflammatory immune response, resulting in 
small-intestinal mucosal injury and malabsorption in ge-
netically susceptible individuals[2]. Currently, the only safe 
and effective treatment is a strict gluten-free diet (GFD) 
combined with nutritional support, which improves 
the health and quality of  life in the vast majority of  pa-
tients[3]. However, a GFD is perceived as a substantial 
burden, particularly due to high costs, dietary restriction, 
reduced social activity, and increased health worries[4].
Gluten proteins are highly abundant in proline (15%) 
and glutamine (35%) residues, particularly in those re-
gions identified as immunogenic in CD[5]. The proline- 
and glutamine-rich peptides in gluten are relatively resist-
ant to proteolysis by gastric, pancreatic and intestinal 
enzymes[6,7]. Consequently, digestion-resistant proline- 
and glutamine-rich peptides can reach the intestinal epi-
thelium intact and can trigger an immune response that 
eventually results in mucosal damage. To eliminate such 
proline-rich gluten peptides, prolyl oligopeptidases, en-
zymes that can cleave after a proline residue in peptides, 
have been investigated by Shan and colleagues[6]. Such en-
zymes, derived from bacteria like Flavobacterium meningosep-
tum, Sphingomonas capsulate and Myxococcus xanthus, were 
capable of  breaking down toxic gluten in vitro[6,8,9]. These 
prolyl oligopeptidases are however not stable and func-
tional under acidic conditions of  the stomach[9,10] and are 
unlikely to degrade gluten epitopes before they reach the 
small intestine. Alternative enzymes that can break down 
gluten are derived from germinating barley and the fun-
gus Aspergillus niger. From the latter a prolyl endoprotease 
termed Aspergillus niger-derived prolyl endoprotease (AN-
PEP) is derived which has distinct advantages over the 
bacterial prolyl oligopeptidase as it degrades both whole 
gluten and gluten peptides into non-immunogenic resi-
dues within minutes[11,12]. Moreover, the enzyme is active 
between pH 2 and pH 8, with an optimum activity at pH 
4-5, and is therefore effective at the pH levels present in 
the stomach and beyond[11,13]. Importantly, the enzyme is 
not degraded by pepsin in the stomach and thus remains 
fully functional. Mitea et al[12] extended these findings by 
showing that AN-PEP degraded toxic gluten proteins in 
a food matrix into non-immunogenic gluten fragments in 
an in vitro digestion model that simulates the human gas-
trointestinal tract. After these promising in vitro results, it 
remains to be established in CD patients whether AN-
PEP can reduce the clinical response to gluten. The aim 
of  this two-phase proof  of  concept study was to dem-
onstrate the safety of  AN-PEP in the first phase and the 
ability of  ANPEP to reduce antibody and histological 
response to gluten consumption by CD patients in the 
second phase of  the study. This information will be im-
portant to further develop AN-PEP as a future digestive 
aid for unintentional ingestion of  gluten by CD patients. 
MATERIALS AND METHODS
Patients
Sixteen adults with CD were recruited at the outpatient 
clinic of  the department of  Gastroenterology and Hepa-
tology of  the VU Medical Centre Amsterdam, The Neth-
erlands. Inclusion criteria were an initial diagnosis of  CD 
as confirmed by histological abnormalities on duodenal 
biopsies classified as a Marsh ⅢB or ⅢC lesion and 
supported by positive serology; endomysium IgA anti-
bodies (IgA-EM) and/or tissue transglutaminase IgA 
antibodies (IgA-tTG). Patients were required to have 
well-controlled CD as evidenced by Marsh 0 or Ⅰ, and 
normalised IgA-EM and IgA-tTG on a strict GFD for at 
least one year. Women at fertile age were required to take 
adequate contraception measures. Reasons for exclusion 
were: use of  any anticoagulant or immunoregulatory 
drug within the last 6 mo; clinically suspected bleeding 
tendency; pregnancy or breast feeding; presence of  any 
concurrent active infection; and IgA deficiency. 
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Design and intervention
The intervention was performed between May 2008 and 
April 2009. The intervention consisted of  two periods, 
each lasting 2 wk (Figure 1). The first study phase was an 
open-label period designed to assess the safety of  high 
gluten intake with AN-PEP (safety phase). The second 
phase was a randomised, double-blind, placebo-control-
led parallel-group study to assess the effect of  AN-PEP 
on gluten-induced clinical response (efficacy phase). 
Sixteen patients with diagnosed CD were enrolled in the 
safety phase. Patients were asked to consume five pieces 
of  toast (in total approximately 7 g gluten, Bolletje®, The 
Netherlands) with AN-PEP-containing topping daily in 
the morning for 2 wk. Patients were allowed to consume 
a glass of  water (250 mL) with their toast. They were 
asked to continue their usual GFD. For ethical reasons, 
patients deteriorating ≥ 2 scales on the histological 
Marsh classification during this safety phase were not 
included in the efficacy phase. Between the study phases, 
a 2-wk washout period was introduced in which patients 
continued their usual GFD. Subsequently, fourteen pa-
tients were randomised in a 1:1 ratio in blocks of  four in 
a double-blind fashion to the same amount of  toast with 
AN-PEP-containing topping (n = 7) or placebo topping 
(n = 7) for 2 wk while remaining on their usual GFD. Pa-
tients’ compliance with the product intake was checked 
by regular telephone contact.
Before and during the study phases, the patients visit-
ed the outpatient clinic five times (Figure 1). During the 
safety phase, blood was collected one week before (base-
line), and one and two wk after start of  gluten with AN-
PEP consumption. During the efficacy phase, blood was 
collected at one and two wk after start of  gluten with 
AN-PEP or placebo consumption. Duodenal biopsies 
were taken at baseline and at the end of  the safety phase 
and the end of  the efficacy phase. Both in the safety and 
efficacy phase, participants were asked to complete a 
celiac disease-specific health-related quality of  life ques-
tionnaire for adults[14] at baseline and after two wk of  
intervention. Biopsies and blood sampled at the end of  
the safety phase were used as baseline values to limit the 
burden for the patients. 
AN-PEP enzyme
The AN-PEP and placebo topping were prepared by 
DSM Food Specialties, Delft, The Netherlands. Both top-
pings (18.5 g) contained 8.2 wt% sucrose, 8.2 wt% sac-
charine solution (400 mg/L saccharine plus 4000 mg/L 
cyclamate), 0.4 wt% citric acid (Jungbunzlauer, Basel, 
Switzerland), 0.08 wt% potassium sorbate (Interland 
Chemie, Oosterhout, The Netherlands), 0.31 wt% so-
dium benzoate (Prolabo, Leuven, Belgium), and 1.23 
wt% xanthane gum Keltrol RD (CP Kelcko, Nijmegen, 
The Netherlands). The AN-PEP topping contained 
81.5 wt% AN-PEP enzyme concentrate corresponding 
with 168 Proline Protease Units of  enzyme activity. The 
placebo topping contained 81.5 wt% distilled water with 
0.06 wt% Plantex® MDA31 (colouring agent, DSM Food 
Specialties, Delft, The Netherlands) to match for colour 
differences. The aroma, flavour and consistency of  the 
topping with AN-PEP were identical to those with pla-
cebo and both toppings could not be distinguished. Mi-
crobial counts and enzyme activity of  the AN-PEP and 
placebo toppings were analysed monthly. All microbial 
counts remained below 10 CFU/g and the activity of  the 
enzyme was maintained at 9.1 ± 0.3 PPU/g topping dur-
ing 12 mo shelf  life at 4  ℃. The AN-PEP and placebo 
toppings were identical in taste and appearance. They 
were pre-packed in containers (14 per box) by DSM and 
consecutively numbered for each patient according to 
the randomisation schedule (prepared by the DSM stat-
istician). 
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Figure 1  Study design and flowchart. In the safety phase, 16 patients daily consumed 5 pieces of toast with Aspergillus niger prolyl endoprotease (AN-PEP) for 2 
wk while continuing their gluten-free diet (GFD). Two patients deteriorated on Marsh scores and were excluded. After a 2-wk wash-out period during which the patients 
continued their usual GFD, the remainder of 14 patients were randomized to the efficacy phase to receive 2 wk of toast with either AN-PEP or placebo while continu-
ing their GFD. CDQ: Celiac disease quality.
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Mucosal biopsy immunophenotyping of  lympho-
cytes: Multiparameter flow cytometric immunophe-
notyping of  mucosal intraepithelial and lamina propria 
lymphocytes was performed. These lymphocytes were 
isolated from six duodenal biopsy specimens per time 
point through chemical and enzymatic dissociation[16]. 
The cells were stained with fluorescein isothiocyanate, 
phycoerythrin, peridinin chlorophyll protein and allophy-
cocyanin-labelled monoclonal antibodies directed against 
CD3, CD4, CD8, CD16/56, CD19, CD45, CD45RA, 
HLA-DR, NKG2D, CD25 and TCR gamma-delta (all 
from BD Biosciences, San Jose, CA, United States), and 
appropriate isotype controls were included. Stained cells 
were analysed on a 4-colour flow cytometer (FACSCali-
burTM, BD Biosciences) and the data were analysed using 
CellquestTM software (Becton Dickinson, San Jose, CA, 
United States). Care was taken to analyse only viable cel-
lular events based on light scatter properties. The mean 
fluorescence intensity index as compared to isotype con-
trols was calculated for the markers included.
Mucosal biopsy gluten-specific T-cell lines: Gut-
resident, gluten-reactive T-cells are a hallmark of  CD. 
To demonstrate that all patients possessed such cells, 
polyclonal T-cell lines were generated from small intes-
tinal biopsies as described[17]. The resulting T-cell lines 
were tested for reactivity against a pepsin/trypsin digest 
of  gluten and a pepsin/trypsin digest of  gluten that 
had been treated with tissue transglutaminase in a T-cell 
proliferation assay as described[17]. In all patients gluten 
reactivity could be demonstrated (not shown). 
Mucosal biopsy IgA-tTG deposits: Biopsies at the 
end of  the randomisation study phase were stained for 
tTG-related extracellular IgA deposits and, in case of  
positivity, baseline biopsies were stained as well. Twelve 
unfixed, 5 μm-thick frozen sections were examined per 
patient by double immunofluorescent labelling of  IgA 
(green) and tTG (red) as previously described[18]. IgA is 
normally detected only inside plasma cells and at the lu-
minal surface, whereas in active CD, subepithelial depos-
its composed of  IgA-tTG are found along the surface 
and crypt basement membranes and around mucosal 
vessels, corresponding to the intestinal localisation of  
tTG. The CD-type IgA-tTG deposits were graded from 
0 to 3 according to their intensity along the basement 
membranes in the villous-crypt area. As this study of  the 
small intestinal IgA-tTG deposits is highly subjective, it 
was performed by an independent specialist in this field 
in a blind manner to greatly increase its accuracy.
Serum antibodies: Blood samples were collected by 
venipuncture to analyse CD-associated antibodies. Levels 
of  IgA-tTG, gliadin IgA antibodies (IgA-AG) and glia-
din IgG antibodies (IgG-AG) were determined with a 
standard in house enzyme-linked immunosorbent assay 
(ELISA), using recombinant human tissue transglutamin-
Blinding
Each patient was assigned a random order number and 
received from the physician the containers in the cor-
responding non-transparent pre-packed box. The al-
location sequence was concealed from the researcher 
enrolling and assessing participants in sequentially 
numbered sealed non-transparent envelopes. Envelopes 
were opened only after completion of  the trial and as-
sessments. All patients, investigators, care providers, and 
staff  assessing outcomes were kept blind to treatment 
assignment. 
Measurements
Mucosal biopsy immunohistology and immunopheno-
typing of  lymphocytes, and serum antibodies were mea-
sured in the service laboratories of  the VU University 
Medical Centre (Amsterdam, The Netherlands). Mucosal 
biopsy gluten-specific T-cell lines were measured in the 
research laboratory of  the Leiden University Medical 
Centre (Leiden, The Netherlands). Mucosal biopsy IgA-
tTG deposits were analysed at the University of  Debre-
cen (Hungary). 
Adverse event reporting: Tolerability of  the gluten intake 
with AN-PEP or placebo was assessed by adverse event 
reporting to the physician during visits. All complaints 
were documented throughout the study. The study de-
sign did not allow for differentiation between complaints 
resulting from gluten or treatment. A difference in com-
plaints between the AN-PEP and placebo group during 
the efficacy phase may give an indication of  treatment-
related effects. 
Celiac-disease quality of  life: All participants were 
asked to complete at home the CD quality of  life ques-
tionnaire, which was translated into Dutch. The CD 
quality of  life questionnaire included four disease-
specific and health-related categories (emotional prob-
lems, social problems, disease-related worries, and 
gastrointestinal symptoms) with 7 items each[14]. Each 
question was weighed on a scale of  1-7 points, a high 
score corresponding to a high level of  well-being. In 
total 196 points could be obtained, with a maximum of  
49 points for each separate category. A change of  12 or 
more points on the total score or of  3 or more on the 
different categories was considered a clinically relevant 
change[14].
Mucosal biopsy immunohistology: Twelve duodenal 
mucosal spike biopsies were taken through upper gastro-
intestinal endoscopy. Four paraffin-embedded biopsies 
were sectioned and hematoxylin-eosin-stained for histo-
logical evaluation according to the modified Marsh clas-
sification[15]. At least two grades increase in the Marsh 
scale was considered a clinically significant deterioration. 
Six fresh biopsies were used for flow cytometric analysis 
and two were snap frozen in liquid nitrogen and stored. 
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ase (Diarect AG, Freiburg, Germany) and gliadin extract 
(Sigma-Aldrich, Zwijndrecht, the Netherlands) as sub-
strates, respectively. IgA-EM antibodies were determined 
by an in-house indirect immunofluorescence test accord-
ing to Lerner using monkey oesophagus as substrate[19]. 
IgA deficiency was excluded to avoid false negative serol-
ogy. In addition, in retrospect a combined test for IgA 
and IgG antibodies directed against human tissue trans-
glutaminase and deamidated gliadin-derived peptides 
(IgA/G-DGP-tTG; tTG/DGP Screen ELISA, INOVA 
Diagnostics, San Diego, United States) was performed[20]. 
References values for antibodies were categorized into 
negative, dubious, weak positive, positive, and strong 
positive. Reference ranges for IgA-AG were < 2.4, 2.5-3.9, 
4.0-20, 20-80, and > 81 U/mL, for IgG-AG, < 11, 12-20, 
21-40, 41-100 U/mL, for IgA-tTG, < 2.9, 3.0-5.9, 6.0-20, 
21-50, > 51 U/mL, and for IgA/G-DGP < 6.9, 7.0-10.9, 
11-30, 31-100 and > 100 U/mL respectively.
Ethical approval
The study was approved by the Medical Ethics Com-
mittee of  the VU Medical Centre and conducted in 
accordance with the guidelines of  the Declaration of  
Helsinki. The trial has been registered in the Dutch Trial 
register (NTR1281) and the FDA Clinical Trial register 
(NCT00810654). A written informed consent was ob-
tained from each subject before enrolment.
Statistical analysis
Data were analysed by OCS Biometric Support (Leiden, 
The Netherlands). Difference from baseline in mucosal 
immunohistology between the two groups after 2 wk 
as measured by Marsh classification was considered the 
primary outcome measure. All other parameters were 
considered secondary endpoints. Power analysis revealed 
that for the detection of  a two-grade difference in the 
Marsh score with a power of  0.80 and a one-sided α level 
of  0.05, 14 patients were needed to finalise the study. 
Data were analysed in the SAS version 9.1, using both 
parametric and non-parametric tests depending on the 
nature of  the data. The quality of  life data were analysed 
with paired t tests to test for differences between data 
before and after the 1st (safety) and 3rd (efficacy) period 
of  the study. Serological and histopathological outcome 
parameters were analysed with Wilcoxon signed-rank 
tests to determine differences between data before and 
after the 1st period and the Wilcoxon rank sum tests to 
test the treatment differences in change from baseline in 
the 3rd period of  the study. In order to explore whether 
patients’ baseline characteristics would predict their re-
sponse to gluten (and hence to increase the chances of  
success in a future trial), rank correlations between base-
line characteristics and outcome variables were explored 
in the placebo group using the Spearman Rank Correla-
tion Coefficient (r) of  the ranked data (analysed by DSM 
Table 1  Demographic and baseline characteristics of the safety and efficacy phase
Safety phase Efficacy phase
Gluten + AN-PEP Gluten + placebo Gluten + AN-PEP
(n  = 16) (n  = 7) (n  = 7)
Patients (n) 16 7 7
Gender (female:male) 12:4 5:2 6:1
Median age at inclusion, yr (range)      55 (20-68)  44 (20-68) 57 (30-64)
Median age at diagnosis, yr (range) 44.5 (0-62) 29 (0-62) 49 (26-53)
Median time on a GFD, yr (range)   7.5 (2-40)  9 (2-40) 8 (4-12)
HLA class (n)
   DQ2/X 12   5   5
   DQ2/DQ2   2   1   1
   DQ2/DQ8   1   0   1
   Unknown   1   1   0
Marsh at inclusion (n)
   Marsh 0 10   4   3
   Marsh Ⅰ   6   3   4
Gastrointestinal symptoms
   Abnormal bowel sounds   4   0   2
   Abdominal pain   5   3   2
   Bowel distension   5   3   1
   Change of defecation   4   2   6
   Constipation   3   2   0
   Diarrhoea   3   1   1
   Dysgeusia   1   1   0
   Flatulence   6   1   2
   Nausea   4   2   0
   Reflux   2   0   1
   Vomiting   1   1   0
   Weight loss   0   1   0
   Total number of symptoms 38 17 15
GFD: Gluten-free diet; AN-PEP: Aspergillus niger prolyl endoprotease. 
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statistician). 
RESULTS
Baseline characteristics
The demographic and baseline characteristics of  the 
patients are presented in Table 1. In total, 16 adults 
on a gluten-free diet diagnosed as having CD [median 
age: 55 (20-68) years] were enrolled in the study. The 
demographic characteristics of  both treatment groups 
were comparable with exception of  the median age at 
diagnosis of  CD, which was 20 years higher in the AN-
PEP compared to the placebo group. The median time 
on GFD treatment was similar in both groups. Two pa-
tients were excluded after the safety phase because of  a 
histological deterioration of  two and three Marsh grades, 
respectively, which for one patient returned to normal 
(Marsh 0) after four weeks of  exclusion. The patient 
that did not return to normal started the study with high 
IgA/G-DGP-tTG values. However, other CD-related 
antibodies remained undetectable in these two patients. 
The remaining 14 patients entered and completed the ef-
ficacy phase. 
When correlating the patients’ baseline characteristics 
with their response to gluten, highly significant inverse 
relationships were found between the patients’ time 
since diagnosis or time spent on a GFD and their re-
sponse to gluten as measured by IgG-AG, IgA-tTG and 
IgA/G-DGP-tTG, and Marsh scores (data not shown).
Adverse events
No serious adverse events occurred during the trial, pa-
tients reported no severe adverse events, and no patients 
withdrew during the trial. Complaints that were reported 
during the safety and efficacy phase were of  gastrointes-
tinal nature and mostly mild and transient. The number 
of  reported gastrointestinal complaints did not differ 
between the AN-PEP and placebo group (Table 1). 
Celiac-disease quality of life
The mean total scores of  the four categories on the CD 
quality of  life were relatively high (145-156 out of  a total 
score of  196) in the total group and throughout both 
study phases. In the safety phase, the total CD quality of  
life score significantly (P = 0.04) increased by 6 points 
during gluten with AN-PEP treatment. This increase was 
however lower than the 12-point increase that is consid-
ered a clinically relevant quality of  life improvement[14]. 
In the efficacy phase, the individual or total CD quality 
of  life scores of  patients consuming gluten with placebo 
or gluten with AN-PEP did not significantly deteriorate. 
No differences between the groups were observed. The 
mean score for the gastrointestinal CD quality of  life 
was relatively high throughout the study, indicating that 
gluten with AN-PEP was well tolerated. 
Mucosal biopsy immunohistology
In the patients receiving gluten plus AN-PEP treatment 
in the safety phase, several patients showed variation in 
Marsh scores but overall no significant change in de-
gree of  mucosal damage, as indicated by changes in the 
Marsh score, was observed (Table 2). Two of  16 patients 
were excluded from entering the efficacy phase as their 
mucosa showed an increase of  two Marsh steps while 14 
patients were considered histologically stable on gluten 
with AN-PEP. Also after the efficacy phase, no signifi-
cant deterioration was observed in the group consuming 
gluten with placebo compared to the group receiving 
AN-PEP.
Mucosal biopsy immunophenotyping of lymphocytes
Flow cytometric analysis of  intestinal lymphocyte sub-
sets showed no significant changes in the expression of  
the T-cell lineage associated markers CD3, CD4, CD8 
and TCR γδ, in either the intraepithelial lymphocyte 
or the lamina propria lymphocyte populations of  both 
treatment groups during the efficacy phase. The mean 
fluorescence index of  the activation markers CD25, 
HLA-DR, the NK receptor and NKG2D as well as 
CD45RA, a marker for naïve T-cells, showed no signifi-
cant change in either group. 
Mucosal biopsy IgA-tTG antibody deposits 
Mucosal tTG-related extracellular IgA deposits are hy-
pothesised to be an early marker for CD activity[21]. De-
spite a GFD, two of  seven patients started with positive 
staining for IgA-tTG at baseline (Table 2). Compared to 
baseline, IgA-tTG deposit staining increased after 2 wk 
of  gluten intake in four out of  seven patients on place-
bo. In the seven patients receiving AN-PEP, one patient 
showed increased and one showed decreased IgA-tTG 
deposits (Table 2, Figure 2). 
Serum antibodies
Serum CD-associated antibodies (IgA-tTG, IgA-EM, 
IgA-AG, IgG-AG and IgA/G-DGP-tTG) were not 
detectable in the serum of  enrolled patients at baseline 
(Table 2) except for one patient in which borderline lev-
els of  IgA/G-DGP-tTG were detected, which became 
negative after 2 wk of  gluten with AN-PEP consump-
tion. The IgA-tTG, IgG-AG, IgA/G-DGP-tTG, and 
IgA-EM antibody titers remained negative on gluten 
with AN-PEP. Three out of  sixteen patients developed 
detectable or borderline IgA-AG levels, while 13 patients 
remained negative during 2-wk of  gluten with AN-PEP 
(Table 2). 
During the efficacy phase, neither the placebo nor 
the AN-PEP group developed significant antibody titers 
(Table 2). The median antibody titers after 2 wk gluten 
intake did not significantly differ between AN-PEP 
and placebo treatment. The IgA-EM concentrations re-
mained negative in both groups.
DISCUSSION
The enzyme AN-PEP might possibly assist in digesting 
Tack GJ et al . AN-PEP in celiac patients
Ta
bl
e 
2 
 S
er
um
 a
nt
ib
od
ie
s,
 d
uo
de
na
l i
m
m
un
oh
ist
ol
og
y 
an
d 
tT
G
A
-A
 a
nt
ib
od
y 
de
po
sit
s 
in
 t
he
 s
af
et
y 
an
d 
ef
fic
ac
y 
ph
as
e 
fo
r 
al
l p
at
ie
nt
s
5843 September 21, 2013|Volume 19|Issue 35|WJG|www.wjgnet.com
un
in
te
nt
io
na
lly
 in
ge
st
ed
 a
m
ou
nt
s o
f 
gl
ut
en
 in
 th
os
e 
w
ho
 c
an
no
t t
ol
er
at
e 
gl
ut
en
. H
ow
ev
er
, d
em
on
st
ra
tin
g 
a 
tre
at
m
en
t e
ffe
ct
 o
n 
(s
m
all
) c
lin
ica
l d
et
er
io
ra
tio
n 
in
du
ce
d 
by
 sm
all
 
am
o
un
ts
 o
f 
gl
ut
en
 in
 t
h
e 
p
la
ce
b
o
 g
ro
up
 m
ay
 b
e 
di
ffi
cu
lt
. T
h
er
ef
o
re
, i
n
 t
h
is
 p
ro
o
f 
o
f 
p
ri
n
ci
p
le
 s
tu
dy
, t
h
e 
en
zy
m
e 
w
as
 g
iv
en
 t
o
 p
at
ie
n
ts
 c
o
n
su
m
in
g 
la
rg
e 
am
o
un
ts
 o
f 
gl
ut
en
 in
 
a 
re
lat
iv
e 
sm
all
 p
er
io
d 
of
 ti
m
e. 
A
 tw
o-
w
ee
k 
sa
fe
ty
 p
ha
se
 (A
N
-P
E
P 
+
 g
lu
te
n)
 p
re
ce
de
d 
th
e 
ra
nd
om
iz
at
io
n 
fo
r A
N
-P
E
P 
or
 p
lac
eb
o 
as
 re
qu
es
te
d 
by
 th
e 
m
ed
ica
l e
th
ica
l c
om
-
m
iss
io
n 
du
e 
to
 c
on
ce
rn
s a
bo
ut
 su
ch
 a
 h
ig
h 
do
se
 o
f 
gl
ut
en
 c
on
su
m
pt
io
n.
 U
nf
or
tu
na
te
ly,
 th
e 
pr
im
ar
y 
aim
 o
f 
th
e 
st
ud
y 
w
as
 n
ot
 m
et
 a
s t
he
 p
lac
eb
o 
ar
m
 d
id
 n
ot
 sh
ow
 a
ny
 d
et
e-
rio
ra
tio
n 
af
te
r 2
 w
k 
of
 g
lu
te
n 
co
ns
um
pt
io
n.
 W
ith
 h
in
ds
ig
ht
, t
he
 st
ud
y 
sh
ou
ld
 p
os
sib
ly 
ha
ve
 b
ee
n 
de
sig
ne
d 
fo
r a
 m
uc
h 
lo
ng
er
 p
er
io
d 
of
 ti
m
e 
w
ith
 m
an
y 
m
or
e 
pa
tie
nt
s.
Th
e 
ba
se
lin
e 
ch
ar
ac
te
ris
tic
s w
er
e 
ba
lan
ce
d 
be
tw
ee
n 
gr
ou
ps
 e
xc
ep
t f
or
 m
ed
ian
 a
ge
 a
t d
iag
no
sis
, w
hi
ch
 w
as
 2
0 
ye
ar
s h
ig
he
r i
n 
th
e 
A
N
-P
E
P 
co
m
pa
re
d 
to
 th
e 
pl
ac
eb
o 
gr
ou
p.
 
H
ow
ev
er
, t
h
is
 is
 u
n
lik
el
y 
to
 h
av
e 
in
fl
ue
n
ce
d 
th
e 
st
ud
y 
o
ut
co
m
e 
as
 n
o
 r
el
at
io
n
sh
ip
 b
et
w
ee
n
 t
h
e 
ag
e 
o
f 
di
ag
n
o
si
s 
an
d 
th
e 
re
sp
o
n
se
 t
o
 g
lu
te
n
 w
as
 o
b
se
rv
ed
 (
da
ta
 n
o
t 
sh
ow
n
).
 
Th
e 
sa
fe
ty
 p
ha
se
 s
ho
w
ed
 th
at
 A
N
-P
E
P 
tre
at
m
en
t, 
w
he
n 
co
ns
um
ed
 w
ith
 a
 h
ig
h 
do
se
 o
f 
ab
ou
t 7
 g
 o
f 
gl
ut
en
 fo
r 2
 w
k,
 w
as
 s
af
e 
in
 p
at
ien
ts
 a
nd
 n
o 
se
ve
re
 a
dv
er
se
 e
ve
nt
s 
w
er
e 
re
po
rte
d.
 T
he
 C
D
 q
ua
lit
y 
of
 li
fe
 sc
or
es
 re
m
ain
ed
 re
lat
iv
ely
 h
ig
h 
du
rin
g 
2 
w
k 
co
ns
um
pt
io
n 
of
 g
lu
te
n 
an
d 
A
N
-P
E
P 
in
di
ca
tin
g 
th
at
 p
at
ien
ts
’ g
en
er
al 
w
ell
-b
ein
g 
re
m
ain
ed
 
hi
gh
. S
er
um
 a
nt
ib
od
ies
 o
f 
th
e 
six
te
en
 p
at
ien
ts
 d
id
 n
ot
 in
cr
ea
se
 w
he
n 
co
ns
um
in
g 
A
N
-P
E
P 
w
ith
 7
 g
 o
f 
gl
ut
en
 fo
r 
2 
w
k.
 A
lso
, h
ist
ol
og
y 
of
 th
e 
bi
op
sie
s 
of
 th
e 
m
ajo
rit
y 
of
 
pa
tie
nt
s 
(fo
ur
te
en
) s
ho
w
ed
 n
o 
de
te
rio
ra
tio
n 
w
hi
le 
tw
o 
pa
tie
nt
s 
de
ve
lo
pe
d 
in
cr
ea
se
d 
M
ar
sh
 s
co
re
s, 
ho
w
ev
er
 n
ot
 a
cc
om
pa
ni
ed
 b
y 
in
cr
ea
se
d 
an
tib
od
ies
. T
he
 s
af
et
y 
ph
as
e 
w
as
 
su
b
je
ct
 t
o
 a
 s
o
-c
al
le
d 
“c
ei
lin
g 
ef
fe
ct
” 
b
ec
au
se
 p
at
ie
n
ts
 e
n
te
re
d 
th
e 
st
ud
y 
o
n
 a
 G
F
D
 r
efl
ec
ti
n
g 
re
la
ti
ve
ly
 h
ea
lt
hy
 b
as
el
in
e 
va
lu
es
, l
im
it
in
g 
th
e 
ab
ili
ty
 t
o
 d
em
o
n
st
ra
te
 a
n
y 
fu
rt
h
er
 
im
pr
ov
em
en
t b
y 
A
N
-P
E
P.
 
P
at
ie
n
ts
 in
 t
h
e 
p
la
ce
b
o
 g
ro
up
 d
id
 n
o
t 
sh
ow
 s
ig
n
ifi
ca
n
t 
de
te
ri
o
ra
ti
o
n
 o
n
 a
n
y 
o
f 
th
e 
m
ea
su
re
d 
cl
in
ic
al
 v
ar
ia
b
le
s 
af
te
r 
a 
2-
w
k 
gl
ut
en
 c
h
al
le
n
ge
, i
n
di
ca
ti
n
g 
th
at
 2
 w
k 
o
f 
gl
ut
en
 
ch
al
le
n
ge
 i
s 
in
su
ffi
ci
en
t 
to
 i
n
du
ce
 a
 c
le
ar
 c
lin
ic
al
 r
es
p
o
n
se
 i
n
 t
h
is
 p
o
p
ul
at
io
n
 o
f 
ce
lia
c 
p
at
ie
n
ts
. D
ue
 t
o
 l
ac
k 
o
f 
re
sp
o
n
se
 t
o
 g
lu
te
n
 i
n
 t
h
e 
p
la
ce
b
o
 a
rm
, n
o
 t
re
at
m
en
t 
ef
fe
ct
 o
f 
B
as
el
in
e
Sa
fe
ty
 p
ha
se
Ef
fic
ac
y 
ph
as
e
2
 w
k 
gl
ut
en
 +
 A
N
-P
EP
2
 w
k 
gl
ut
en
 +
 A
N
-P
EP
 o
r 
pl
ac
eb
o
Se
ru
m
B
io
ps
y
Tx
Se
ru
m
B
io
ps
y
Tx
Se
ru
m
B
io
ps
y
Ig
A
-t
TG
Ig
A
-A
G
Ig
G
-A
G
Ig
A
/G
-D
G
P-
tT
G
M
ar
sh
Ig
A
-t
TG
 d
ep
os
it
s
Ig
A
-t
TG
Ig
A
-A
G
Ig
G
-A
G
Ig
A
/G
-D
G
P-
tT
G
M
ar
sh
Ig
A
-t
TG
Ig
A
-A
G
Ig
G
-A
G
Ig
A
/G
-D
G
P-
tT
G
M
ar
sh
Ig
A
-t
TG
 d
ep
os
it
s
1
-
-
-
-
I
N
D
A
-
-
-
-
0
P
-
-
-
-
I
0
2
-
+/
-
-
-
0
0
A
-
+
-
-
I
P
-
++
+
-
Ⅲ
A
1-
2
3
-
-
-
-
I
0
A
-
-
-
-
I
P
-
-
-
-
Ⅲ
A
1-
2
4
+/
-
-
-
+
I
1
A
-
-
-
+
0
P
+
-
-
++
I
2-
3
5
-
-
-
-
0
N
D
A
-
-
-
-
0
P
-
-
-
-
0
0
6
-
-
-
-
0
0
A
-
-
-
-
0
P
-
-
-
-
0
1
7
-
-
-
-
0
0
A
-
-
-
-
0
P
-
-
-
-
I
1-
2
8
-
-
-
-
I
N
D
A
-
-
-
-
Ⅱ
A
-
-
-
-
I
0
9
-
-
-
-
0
3
A
-
-
-
-
I
A
-
+/
-
-
+
I
1
10
-
-
-
-
0
N
D
A
-
+/
-
-
-
I
A
-
+/
-
+
+
I
0
11
-
-
-
-
I
0
A
-
+
-
-
II
A
-
+/
-
-
-
Ⅲ
A
1
12
-
-
-
-
I
N
D
A
-
-
-
-
I
A
-
-
-
-
I
0
13
-
-
-
-
0
N
D
A
-
-
-
-
0
A
-
-
-
-
0
0
14
-
-
-
-
0
N
D
A
-
-
-
-
0
A
-
-
-
-
0
0
15
-
-
-
++
0
N
D
A
-
-
-
++
Ⅱ
E
-
-
-
++
Ⅲ
A
N
D
16
-
-
-
-
0
N
D
A
-
-
-
-
Ⅲ
A
E
-
-
-
-
0
N
D
T
h
e 
se
ru
m
 E
M
A
-A
 a
n
ti
bo
d
ie
s 
re
m
ai
n
ed
 n
eg
at
iv
e 
in
 a
ll
 p
at
ie
n
ts
 d
u
ri
n
g 
th
e 
en
ti
re
 s
tu
d
y.
 M
u
co
sa
l t
T
G
A
-A
 d
ep
os
it
s 
w
er
e 
gr
ad
ed
 f
ro
m
 0
 t
o 
3.
 T
x:
 T
re
at
m
en
t; 
A
: A
N
-P
E
P
; P
: P
la
ce
bo
; E
: E
xc
lu
d
ed
; I
gA
-t
T
G
: A
n
ti
-t
is
su
e 
tr
an
sg
lu
ta
m
i-
na
se
 Ig
A
 a
nt
ib
od
ie
s;
 Ig
A
-G
A
: A
nt
i-g
lia
di
n 
Ig
A
 a
nt
ib
od
ie
s;
 Ig
G
-G
A
: A
nt
i-g
lia
di
n 
Ig
G
 a
nt
ib
od
ie
s;
 Ig
A
/G
-D
G
P-
tT
G
: A
nt
i-t
is
su
e 
tr
an
sg
lu
ta
m
in
as
e 
an
d 
de
am
id
at
ed
 g
lia
di
n-
de
ri
ve
d 
pe
pt
id
e 
Ig
A
 a
nd
 Ig
G
 a
nt
ib
od
ie
s;
 I-
FA
BP
: I
nt
es
tin
al
 
fa
tty
 a
ci
d 
bi
nd
in
g 
pr
ot
ei
n;
 N
D
: N
ot
 d
et
er
m
in
ed
. -
: N
eg
at
iv
e;
 +
/-
: D
ub
io
us
; +
: W
ea
k 
po
si
tiv
e;
 +
+:
 P
os
iti
ve
; +
++
: S
tr
on
g 
po
si
tiv
e.
Tack GJ et al . AN-PEP in celiac patients
5844 September 21, 2013|Volume 19|Issue 35|WJG|www.wjgnet.com
Figure 2  Small intestinal tissue transglutaminase IgA antibody deposits (rated on a scale 0-3) in two patients at baseline and after randomization to As-
pergillus niger prolyl endoprotease and placebo respectively. A: Baseline evaluation of patient 1 showed preserved villous architecture (arrow), with intense, 
grade 3 IgA depositions (green) subepithelially and around crypts; B: This deposition merges to yellow indicating co-localisation with tTG shown in red; C: In this 
patient, IgA deposits diminished after 2 wk Aspergillus niger prolyl endoprotease (AN-PEP) treatment to grade 1, when only faint and patchy antibody deposition was 
seen (arrow); D: tTG appeared in red in this AN-PEP-treated patient (arrow) in the absence of IgA deposition. The cell nuclei were stained with 4',6-diamidino-2-phe-
nylindole (DAPI) (blue); E: Baseline evaluation of patient 2 showed preserved villous architecture with faint, grade 1 IgA deposition in the deep mucosal layer around 
Brunner glands (arrow); F: This deposition were not sufficient to obtain a yellow colour at merging with tTG shown in red (asterisk); G: In this patient, IgA deposition 
increased to grade 2 subepithelially (arrow) after 2 wk placebo; H: IgA deposition increased to grade 3 in the crypt region after 2-wk placebo (arrow). IgA deposition 
co-localised with tTG to intense yellow (arrow). The cell nuclei were stained with DAPI (blue). 
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AN-PEP could be detected. The measured serum levels 
of  IgA-tTG, IgA-EM, and IgA/G-DGP-tTG antibod-
ies are considered sensitive markers of  CD and should 
be able to detect subtle immunogenic effects of  gluten. 
Similarly, the CD-specific quality of  life questionnaire 
is considered a CD-specific measure of  quality of  life 
and should also be able to pick up relevant changes in 
health[14]. However, histological examination of  small in-
testinal biopsies may be less reliable than CD-associated 
antibodies due to heterogeneous distribution of  lesions, 
low grade histopathology, and intra- and interobserver 
variability[22]. Interestingly, measures of  clinical response 
to gluten (Marsh scores, antibody titres, quality of  life 
scores) did not correlate in this study, which may in part 
be explained by the lack of  response to gluten. The 
IgA antibody reactivity to small intestinal mucosa tTG 
has been considered to be an early marker for gluten-
induced pathology in CD patients[23]. It was observed 
that intestinal IgA-tTG deposits can be detected in latent 
CD patients in whom the mucosal villous architecture 
is still intact, and that the intensity of  these mucosal de-
posits decreased after adherence to a GFD and increased 
after gluten consumption. Although numbers were low, 
mucosal IgA-tTG deposits increased in four patients on 
placebo and one on AN-PEP and decreased in one pa-
tient on AN-PEP, compared to baseline values, suggest-
ing that AN-PEP may mitigate gluten exposure. 
Some gastrointestinal-related symptoms, mostly mild 
and transient, were reported during gluten challenge and 
symptoms between the two groups were comparable 
suggesting no treatment-related effects on gastrointes-
tinal symptoms. Besides the substantial gluten intake, 
emotional stress as a consequence of  having to ingest 
gluten might have triggered some of  the reported gas-
trointestinal complaints. 
The celiac patients consumed approximately 7 g of  
gluten daily, which is about half  of  the average adult 
daily gluten intake in The Netherlands[24]. Despite this 
high gluten dose, no substantial histological, serological, 
or symptom changes were observed with placebo after 
2 wk. In another study[25] in which adult CD patients 
consumed approximately 3.5 g/d of  gluten from cracker 
biscuits for 2 wk, only few patients consuming gluten 
on placebo showed deterioration on histology, serology, 
and symptoms. Two other studies investigating a gluten 
challenge in adult patients, based on either lower gluten 
intake (2.5-5.0 g/d for at least 3 mo)[26] or comparable 
gluten intake (4 slices of  white bread daily; approximate-
ly 8 g/d)[27] showed that a moderate gluten intake can be 
tolerated by some patients for several weeks-to-months 
without significant changes in symptoms[27], serology[26] 
and histology[26,27]. The time to serological and mucosal 
relapse and recovery after gluten re-introduction and 
elimination, respectively, can be highly variable among 
adult CD patients from several weeks up to many 
years[27-30]. Excluding 2 out of  16 patients that may have 
been more sensitive to gluten from the efficacy phase 
may, to a small extent, have caused sample bias by select-
ing patients being less sensitive to gluten. Nevertheless, 
the same population of  patients that entered the efficacy 
phase was randomly allocated to the AN-PEP or placebo 
arm. Also attrition bias can be excluded since all patients 
remained in the study. The lack of  substantial clinical 
response to gluten observed in this study indicates that 
a longer gluten challenge is likely necessary to induce a 
significant clinical response to gluten in the majority of  
patients. For the same reason a longer wash-out period 
should be considered. Moreover, unresponsiveness to 
gluten of  patients being diagnosed for more than 10 
years ago, suggests that future studies may benefit from 
selecting more recently diagnosed patients.
In conclusion, AN-PEP appeared to be safe in celiac 
patients. More patients and gluten challenge for a longer 
period of  time seem to be required to induce significant 
clinical changes and to confirm whether the tendency of  
AN-PEP to reduce small bowel IgA-tTG deposits is of  
clinical significance. These results together with previous 
in vitro evidence that AN-PEP efficiently degrades gluten 
under simulated gastrointestinal conditions warrant con-
firmation in a larger trial. 
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The celiac disease quality of life scores remained relatively high during 2 
wk consumption of gluten and AN-PEP indicating that patients’ general well-
being remained high. The enzyme AN-PEP might possibly assist in digesting 
unintentionally ingested amounts of gluten in those who cannot tolerate gluten. 
However, the primary aim of the study was not met as the placebo arm did not 
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